Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

March 2014 - FRMC

Department

News Connection
03/18/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
Results of 2 phase 3, multicenter, randomized, double-blind trials show no clinical benefit of bapineuzumab to treat patients with mild-to-moderate Alzheimer’s disease (AD) [N Engl J Med. 2014;370:322-33].   The study did find, however, that...
Results of 2 phase 3, multicenter, randomized, double-blind trials show no clinical benefit of bapineuzumab to treat patients with mild-to-moderate Alzheimer’s disease (AD) [N Engl J Med. 2014;370:322-33].   The study did find, however, that...
Results of 2 phase 3,...
03/18/2014
First Report Managed Care
News Connection
03/18/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
Results of two phase 2, randomized, double-blind trials showed that solanezumab does not improve cognition or functional ability in patients with mild-to-moderate Alzheimer’s disease (AD) [N Engl J Med. 2014;370:311-321].
Results of two phase 2, randomized, double-blind trials showed that solanezumab does not improve cognition or functional ability in patients with mild-to-moderate Alzheimer’s disease (AD) [N Engl J Med. 2014;370:311-321].
Results of two phase 2,...
03/18/2014
First Report Managed Care
Managed Care Q&A
03/18/2014
First Report Managed Care conducted an interview with Gary Owens, MD, one of our Editorial Advisory Board members, to discuss the changing climate of benefit management and drug approvals under the Patient Protection and Affordable Care Act...
First Report Managed Care conducted an interview with Gary Owens, MD, one of our Editorial Advisory Board members, to discuss the changing climate of benefit management and drug approvals under the Patient Protection and Affordable Care Act...
First Report Managed Care...
03/18/2014
First Report Managed Care
Conference Insider
03/18/2014

Tim Casey

Tim Casey
New York—When GlycoMimetics, Inc., developed its program for a promising new drug, the biotechnology company considered not only the medication’s safety and efficacy but also its economic value. Other pharmaceutical manufacturers are...
New York—When GlycoMimetics, Inc., developed its program for a promising new drug, the biotechnology company considered not only the medication’s safety and efficacy but also its economic value. Other pharmaceutical manufacturers are...
New York—When GlycoMimetics,...
03/18/2014
First Report Managed Care
03/18/2014

Sarah O'Brien

Sarah O'Brien
The results of the recently released MORE (Metastatic Colorectal Cancer Liver Metastases Outcomes after Radio Embolization) study found standard laboratory tests have been confirmed as a means of predicting patient outcomes prior to selective...
The results of the recently released MORE (Metastatic Colorectal Cancer Liver Metastases Outcomes after Radio Embolization) study found standard laboratory tests have been confirmed as a means of predicting patient outcomes prior to selective...
The results of the recently...
03/18/2014
First Report Managed Care
03/18/2014

Mary Mihalovic

Mary Mihalovic
The computerized clinical surveillance system (CSS), known as TheraDoc, is used to increase Centers for Medicare & Medicaid Services (CMS) core measure compliance among patients with acute myocardial infarction (MI). CSS was recently studied...
The computerized clinical surveillance system (CSS), known as TheraDoc, is used to increase Centers for Medicare & Medicaid Services (CMS) core measure compliance among patients with acute myocardial infarction (MI). CSS was recently studied...
The computerized clinical...
03/18/2014
First Report Managed Care
03/18/2014

Mary Mihalovic

Mary Mihalovic
The use of asynchronous, or nonconcurrent, Internet-based communication in healthcare is likely an important tool to increase patient participation and self-management, according to results of a recent literature review [J Med Internet Res....
The use of asynchronous, or nonconcurrent, Internet-based communication in healthcare is likely an important tool to increase patient participation and self-management, according to results of a recent literature review [J Med Internet Res....
The use of asynchronous, or...
03/18/2014
First Report Managed Care
03/18/2014

Tim Casey

Tim Casey
Las Vegas—Since Walmart introduced its $4 program for generic drugs and over-the-counter medications in 2006, the largest retail company in the United States has become a major figure in healthcare. The company is now hoping to expand,...
Las Vegas—Since Walmart introduced its $4 program for generic drugs and over-the-counter medications in 2006, the largest retail company in the United States has become a major figure in healthcare. The company is now hoping to expand,...
Las Vegas—Since Walmart...
03/18/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement